Tonix Pharmaceuticals Holding Corp. (TNXP) on Monday said it plans to start a Phase 2 study of TNX-2900 for the treatment of Prader-Willi syndrome, a genetic disorder that affects multiple parts of the body, in 2026.
The announcement follows clearance from the U.S. Food and Drug Administration (FDA) to advance the program into Phase 2.
The study will assess the safety, tolerability, and efficacy of TNX-2900 in male and female participants with Prader-Willi syndrome, aged 8 to 17.5 years.
TNX-2900 has received Orphan Drug and Rare Pediatric Disease designations from the FDA, making it eligible for a potential Priority Review Voucher upon approval.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.